On January 4, 2024, Stemline Therapeutics, Inc. (Stemline), a wholly owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, announced they have entered into an exclusive licensing agreement granting Stemline global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico's AI platform as a potential treatment for hormone sensitive cancers and other oncology indications. Under the terms of the agreement, Stemline will pay to Insilico a $12 million upfront payment; potential development, regulatory, and commercial milestones in excess of $500 million; and royalties.

Wilson Sonsini Goodrich & Rosati represented Insilico in the transaction. The Wilson Sonsini team includes technology transactions attorneys Alex Key and Kexi Wang; patents and innovations attorneys Mike Hostetler, Ying Chen, and Richard Wang; and patent agent Céline Bonnefous.

For more information, please see the press release.